Mandate

Vinge advises on Medivir’s new issue

March 29, 2010

Medivir AB (publ) (NASDAQ OMX Stockholm) is performing a rights issue for approximately SEK 300 million. The new issue is fully covered by subscription undertakings, declarations of intent and underwriting undertakings from, among others, Carnegie and Jefferies acting as Joint Bookrunners.

Vinge is advising Medivir. Vinge’s team consists of Erik Sjöman, Emil Hedberg and Jesper Schönbeck. In addition, Rikard Stenberg, Maria Doeser and Markus Larsson have been involved in the transaction.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025